Quantcast

Latest JVS-100 Stories

2014-08-12 08:31:39

CLEVELAND, Aug. 12, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it successfully completed the Phase I arm of the RETRO-HF clinical trial, and fully enrolled the Phase II arm that is evaluating the safety and preliminary clinical efficacy for retrograde infusion of JVS-100 in patients with heart failure....

2011-04-26 07:00:00

CLEVELAND, April 26, 2011 /PRNewswire/ -- Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that it has successfully completed its Phase I clinical trial evaluating the safety and preliminary efficacy of JVS-100 for treatment of patients with heart failure. Complete results from the trial will be reported at the 2011 Annual Meeting for the American Society for Gene & Cell Therapy on May 19th in...

2010-04-05 07:00:00

CLEVELAND, April 5 /PRNewswire/ -- Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related